Patents Examined by James L Rogers
  • Patent number: 11192919
    Abstract: The invention provides for the removal of a large fraction of contaminants from protein preparations while maintaining a high level of recovery using tentacle anion exchange matrix chromatography medium. Using the methods of the invention, leached affinity chromatography contaminants can be removed from recombinant protein preparations.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: December 7, 2021
    Assignee: AMGEN INC.
    Inventors: Samuel Ray Trejo, Robert Perry Brake
  • Patent number: 11180536
    Abstract: Antibodies specific for royalactin (RA) can be used in methods for purifying royalactin, including native royalactin. These methods produce can produce compositions enriched for native royalactin. The purified royalactin can be used to produce cosmetic products that include native royalactin. An isolated nucleic acid encodes a monoclonal antibody that binds specifically to royalactin.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: November 23, 2021
    Assignee: WYL SCIENCES INC.
    Inventors: George P. Yang, Kevin C. Wang, Derrick C. Wan
  • Patent number: 11136609
    Abstract: An object of the present invention is to provide a separation agent for separating a human serum-derived IgG polyclonal antibody. This object is achieved by a separation agent for separating a human serum-derived IgG polyclonal antibody, the separation agent including: a carrier; and a single-chain antibody which has a dissociation constant for a human serum-derived IgG polyclonal antibody of not more than 3.0×10?8 M and which binds to the surface of the carrier via a chemical bond.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: October 5, 2021
    Assignees: NATIONAL UNIVERSITY CORPORATION KYOTO INSTITUTE OF TECHNOLOGY, DAICEL CORPORATION
    Inventors: Yoichi Kumada, Yuya Hasegawa, Seiichi Uchimura
  • Patent number: 11136350
    Abstract: The present invention provides improved methods for the manufacturing of IVIG products. These methods offer various advantages such as reduced loss of IgG during purification and improved quality of final products. In other aspects, the present invention provides aqueous and pharmaceutical compositions suitable for intravenous, subcutaneous, and/or intramuscular administration. In yet other embodiments, the present invention provides methods of treating a disease or condition comprising administration of an IgG composition provided herein.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: October 5, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Leopold Bruckschwaiger, Sonja Svatos, Julia Nuernberger, Wolfgang Teschner, Harald Butterweck, Hans-Peter Schwarz, Thomas Gundinger, Bernhard Koelbl, Reinhard Grausenburger, Azra Pljevljakovic
  • Patent number: 11111269
    Abstract: Various aspects and embodiments of the present disclosure relate to the purification antibodies by hydrophobic interaction chromatography under no-salt conditions.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: September 7, 2021
    Assignee: Biogen MA Inc.
    Inventors: Sanchayita Ghose, Yinying Tao
  • Patent number: 11098079
    Abstract: Methods of producing an aqueous formulation of an antigen-binding protein or enhancing re-oxidation of an antigen-binding protein are disclosed. The methods comprise (a) contacting an aqueous solution comprising antigen-binding protein molecules with a charged depth filter under conditions sufficient to enhance re-oxidation of the antigen-binding protein molecules and achieve a decrease in the percentage of reduced antigen-binding protein molecules, compared to the percentage of reduced antigen-binding protein molecules observed prior to step (a); and (b) optionally, measuring the amount or relative amount of reduced antigen-binding protein molecules. Formulations comprising a re-oxidized antigen-binding protein are also described.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: August 24, 2021
    Assignee: AMGEN INC.
    Inventors: Hai Hoang, Rafael Gonzalez, Junfen Ma
  • Patent number: 11084851
    Abstract: The present invention relates to chromatography ligands having improved caustic stability, e.g., ligands based on immunoglobulin-binding proteins such as, Staphylococcal protein A, as well as methods of making and using such ligands.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: August 10, 2021
    Assignee: EMD MILLIPORE CORPORATION
    Inventors: Nanying Bian, Neil Soice, Shari Spector, Kara Levine
  • Patent number: 11085935
    Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.
    Type: Grant
    Filed: September 9, 2020
    Date of Patent: August 10, 2021
    Assignee: Washington University
    Inventors: Nicolas Barthelemy, Randall Bateman, Eric McDade
  • Patent number: 11034754
    Abstract: A method for the purification of immunoglobulins by ion exchange chromatography is described. The chromatographic method uses a weak ion exchange resin and a single step elution process for the purification of an immunoglobulin. Additionally a method for the determination of the salt concentration for the single step elution of an immunoglobulin from an ion exchange resin is described.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: June 15, 2021
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Roberto Falkenstein, Burkard Kolb, Maria Sebald
  • Patent number: 11008397
    Abstract: Provided herein are de novo binding domain containing polypeptides (DBDpp) that specifically bind a target of interest. Nucleic acids encoding the DBDpp, and vectors and host cells containing the nucleic acids are also provided. Libraries of DBDpp, methods of producing and screening such libraries and the DBDpp identified from such libraries and screens are also encompassed. Methods of making and using the DBDpp are additionally provided. Such uses include, without limitation, affinity purification, and diagnostic and therapeutic applications.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: May 18, 2021
    Assignees: Subdomain, LLC, Arcellx, Inc.
    Inventors: David William Lafleur, David M. Hilbert
  • Patent number: 10974166
    Abstract: One embodiment of the present invention is a protein having affinity for an immunoglobulin, which is a protein having two or more domains derived from any of the amino acid sequences of E, D, and A domains of protein A, and in the amino acid sequence of at least one of the domains, one or more lysines are included, and the C-terminal lysine is deleted or substituted, or a protein having affinity for an immunoglobulin, which is a protein having two or more domains derived from any of B, C, and Z domains of protein A, and in the amino acid sequence of at least one of the domains, one or more lysines are included, and lysine at position 4 and the C-terminal lysine are deleted or substituted.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: April 13, 2021
    Assignee: Mitsubishi Chemical Corporation
    Inventors: Shoya Yoda, Satoru Misawa, Risa Nakata
  • Patent number: 10940401
    Abstract: The present invention provides methods for cleaning or regenerating a chromatography materiel for reuse. The methods of the invention can be used for cleaning or regenerating chromatography columns for reuse in the large-scale manufacture of multiple polypeptide products.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: March 9, 2021
    Assignee: GENENTECH, INC.
    Inventors: Ekta Mahajan, Joanna So, Jay Werber
  • Patent number: 10941178
    Abstract: The present disclosure relates generally to methods of producing, processing, or purifying antibodies. The present disclosure also relates to methods of producing, processing, or purifying a target antibody from cell cultures to remove host cell proteins.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: March 9, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Nooshafarin Sanaie, Brian Kluck, Andrew Quezada, Robert vonder Reith, Chi Tran, James Woo
  • Patent number: 10927164
    Abstract: The present invention provides a method for recovering a human VH3 domain-containing antibody in monomeric form. In particular the present invention provides a new method that allows recovery of monomeric human VH3 domain-containing antibodies from a mixture containing monomeric and multimeric forms of the antibody.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: February 23, 2021
    Assignee: UCB BIOPHARMA SRL
    Inventors: Sam Philip Heywood, Gavin Barry Wild
  • Patent number: 10919930
    Abstract: Methods are disclosed for use of apatite chromatography, particularly without reliance upon phosphate gradients, for purification or separation of at least one intact non-aggregated antibody, or at least one immunoreactive antibody fragment, from an impure preparation. Integration of such methods into multi-step procedures with other fractionation methods are additionally disclosed.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: February 16, 2021
    Assignee: Bio-Rad Laboratories, Inc.
    Inventor: Peter S. Gagnon
  • Patent number: 10912955
    Abstract: A process is provided for inhibiting symptoms of celiac disease, Clostridium difficile associated diseases such as Clostridium difficile colitis, pseudomembranous colitis and antibiotic associated diarrhea, food allergy or food intolerance in a subject that includes the oral administration to the subject suffering from food allergy or food intolerance an IgM. When administered in a, therapeutic quantity based on the subject characteristics and the type of IgM, symptoms of food allergy or food intolerance in that subject are inhibited. Even non-secretory forms of IgM are effective when administered orally.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: February 9, 2021
    Inventor: Michael R. Simon
  • Patent number: 10906934
    Abstract: The invention provides methods of reducing fouling of ultrafiltration membranes in processes wherein virus particles are removed from aqueous solutions comprising virus particles and at least one protein by adding a surfactant or non-surfactant, non-ionic agent to the aqueous solution prior to filtration. The invention also provides methods to dissociate protein aggregates or to reduce the formation of protein aggregates by adding a surfactant or non-surfactant, non-ionic agent to the protein solution.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: February 2, 2021
    Assignee: GENENTECH, INC.
    Inventors: Arick Brown, Junyan Ji, Jun Liu, Yuchang John Wang
  • Patent number: 10906935
    Abstract: Disclosed here includes a method for purifying a biologic composition, comprising diafiltering the biologic composition into a composition comprising phosphate buffered saline (PBS) to obtain a purified composition. The method disclosed here can be particularly useful for removing one or more impurities from the biologic composition, such as bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane (Bis-tris).
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: February 2, 2021
    Assignees: United Therapeutics Corporation, The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: David Meh, Timothy Atolagbe, G. Mark Farquharson, Samir Shaban, Mary Koleck, George Mitra
  • Patent number: 10894806
    Abstract: The invention relates to a process for the selective concentration of immunoglobulins or other proteins that contain an Fc domain (target protein), comprising the following steps: a. preparing a solution that contains the target protein; b. incorporating an Fc-binding protein with precisely two binding sites under conditions that allow binding to occur; c. separating the precipitate from the liquid phase; d. undoing the binding of the target protein from the Fc-binding protein.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: January 19, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Dorothee Ambrosius, Michael Dieterle, Philine Dobberthien, Maria-Katharina Wiegeshoff
  • Patent number: 10888841
    Abstract: Provided is an affinity chromatography carrier having an excellent purification purity, including a substrate, a hydrophilic polymer, and an affinity ligand, in which the substrate is constituted of at least one selected from the group consisting of a polysaccharide, an acrylate-based polymer, a methacrylate-based polymer and a styrene-based polymer, the hydrophilic polymer is at least one selected from the group consisting of hydrophilic polysaccharides, the affinity ligand is at least one selected from the group consisting of an antibody-binding protein and an antibody-binding polypeptide, a carboxy group is introduced into the affinity chromatography carrier, and the amount of the carboxy group introduced is 15 mmol/L-gel to 60 mmol/L-gel in terms of ion exchange capacity.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: January 12, 2021
    Assignee: FUJIFILM Corporation
    Inventor: Shiori Kihara